RNA m6A阅读蛋白YTHDF2维持胶质母细胞瘤干细胞致癌基因表达并可靶向
该研究通过m6A RNA免疫沉淀测序和转录组分析,发现胶质母细胞瘤干细胞(GSC)中m6A标记的转录本较正常神经干细胞(NSC)常上调。GSC优先表达YTHDF2并在体内外依赖其功能,YTHDF2以m6A依赖方式稳定MYC和VEGFA转录本。IGF1/IGF1R抑制剂linsitinib优先靶向YTHDF2表达细胞,抑制GSC活力而不影响NSC,并损害体内胶质母细胞瘤生长。
要点
- GSC中m6A标记转录本较NSC常上调,YTHDF2在GSC优先表达并具体内外依赖性。
- YTHDF2以m6A依赖方式稳定MYC和VEGFA转录本,IGFBP3为其下游效应因子。
- linsitinib优先靶向YTHDF2表达细胞,抑制GSC活力且不影响NSC,损害体内肿瘤生长。
核心结论
- YTHDF2连接RNA表观转录修饰与GSC生长,YTHDF2-MYC-IGFBP3轴是胶质母细胞瘤特异性新治疗靶点。
研究设计与样本
- 研究对GSC进行m6A RNA免疫沉淀测序和转录组分析,并与正常NSC比较。
- 研究评估了m6A调节因子在GSC与NSC中的表达及体内外依赖性。
主要发现
- GSC中m6A标记的转录本较正常NSC常上调。
- GSC优先表达YTHDF2并在体内外依赖其功能,而NSC不依赖。
- YTHDF2以m6A依赖方式稳定GSC中MYC和VEGFA转录本。
- IGFBP3被鉴定为GSC中YTHDF2-MYC轴的下游效应因子。
- linsitinib优先靶向YTHDF2表达细胞,抑制GSC活力而不影响NSC,并损害体内胶质母细胞瘤生长。
临床怎么用
- YTHDF2及其下游MYC-IGFBP3轴可作为胶质母细胞瘤干细胞靶向治疗的候选方向。
- IGF1/IGF1R抑制剂linsitinib对YTHDF2表达细胞具有优先靶向性,提示潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma is a universally lethal cancer driven by glioblastoma stem cells (GSC). Here, we interrogated N 6-methyladenosine (m6A) mRNA modifications in GSCs by methyl RNA immunoprecipitation followed by sequencing and transcriptome analysis, finding transcripts marked by m6A often upregulated compared with normal neural stem cells (NSC). Interrogating m6A regulators, GSCs displayed preferential expression, as well as in vitro and in vivo dependency, of the m6A reader YTHDF2, in contrast to NSCs. Although YTHDF2 has been reported to destabilize mRNAs, YTHDF2 stabilized MYC and VEGFA transcripts in GSCs in an m6A-dependent manner. We identified IGFBP3 as a downstream effector of the YTHDF2-MYC axis in GSCs. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. Thus, YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2-MYC-IGFBP3 axis as a specific and novel therapeutic target in glioblastoma. SIGNIFICANCE: Epitranscriptomics promotes cellular heterogeneity in cancer. RNA m6A landscapes of cancer and NSCs identified cell type-specific dependencies and therapeutic vulnerabilities. The m6A reader YTHDF2 stabilized MYC mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma.This article is highlighted in the In This Issue feature, p. 211.
引用
- Dixit D, Prager BC, Gimple RC, et al. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2020. PMID: 33023892. doi:10.1158/2159-8290.CD-20-0331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。